RecruitingNCT05843500

Chronic Thromboembolic Disease Registry

Chronic Thromboembolic Disease: A Prospective Registry

Sponsor

University of California, San Francisco

Enrollment

100 participants

Start Date

Aug 1, 2023

Study Type

OBSERVATIONAL

Conditions

Chronic Thromboembolic Pulmonary Hypertension Chronic Thromboembolic Disease

Summary

The goal of this patient registry is to learn about the natural history in patients with chronic thromboembolic disease (CTD) and/or chronic thromboembolic pulmonary hypertension (CTEPH). The main question\[s\] it aims to answer are: * Long-term outcome after various types of treatment, including medication, balloon pulmonary angioplasty, and pulmonary endarterectomy * Effect of treatment on patient's quality of life and exercise tolerance Participants will be followed longitudinally to assess their health outcomes and quality of life via chart review and health quality surveys.

Eligibility

Min Age: 18 Years

Inclusion Criteria6

Patients referred with CTED and/or CTEPH defined as:
Mean pulmonary arterial pressure (mPAP) \> 20 mmHg at rest with pulmonary vascular resistance (PVR) \> 2 Wood units (WU); or if mPAP ≤ 20 mmHg or PVR ≤ 2 WU at rest, have exercise limitations from chronic thromboembolic pulmonary disease (CTEPD) without pulmonary hypertension (PH)
Radiologic finding of chronic thromboembolic disease, including abnormal ventilation perfusion scan, pulmonary angiogram, computer tomographic pulmonary angiogram, or magnetic resonance pulmonary angiogram
Post-embolic exercise intolerance and evidence of chronic thromboembolic disease in the absence of resting pulmonary hypertension
Treatment with anticoagulation for ≥ 3 months before diagnosis of CTEPH or CTEPD without PH
Age ≥ 18 years

Exclusion Criteria2

Main cause of PH other than World Health Organization (WHO) group 4 (CTEPH)
Patient's refusal to participate in clinical research and/or receive intervention

Interventions

OTHERSurvey

Patients who received medical, surgical or interventional treatment for chronic thromboembolic pulmonary hypertension will be followed and given quality of life questionnaires.